IP Library Granted Patent US 9,005,660
Granted Patent B2
US 9,005,660 · App. 12/701,248 · Granted Apr 14, 2015

Immediate release composition resistant to abuse by intake of alcohol

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,005,660
App. No.
12/701,248
Granted
Apr 14, 2015
Kind
B2
Abstract

The present invention relates to immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol. In particular, this disclosure provides immediate release pharmaceutical compositions comprising a polyglycol having a molecular weight of from about 900 to about 17,000 daltons, a drug substance, one or more effervescent agents, and, optionally, one or more disintegrants, such that the composition is formulated to be resistant to abuse by intake of alcohol.

Claims (25)

1. An immediate release pharmaceutical composition, wherein the composition is resistant to alcohol-induced dose dumping, the composition comprising:

a. one or more drug substances; and

b. a polymer matrix resistant to alcohol-induced dose dumping,

wherein the drug substance is dispersed within the polymer matrix, and wherein the polymer matrix consists essentially of

(i) a polyglycol having a molecular weight of from 900 to about 17,000 Daltons;

(ii) one or more effervescent agents; and

(iii) one or more disintegrants.

2. The immediate release pharmaceutical composition according to claim 1 , wherein the composition is resistant to abuse by intake of alcohol when the alcohol is ingested either:

a. together with the composition, or

b. within a period of up to 60 minutes before and up to 60 minutes after the intake of the composition.

3. The immediate release pharmaceutical composition of claim 1 , wherein the composition is suitable for administration to a patient that ingests three or more alcoholic beverages daily.

4. The immediate release pharmaceutical composition of claim 3 , wherein the composition is resistant to alcohol-induced dose dumping when a patient to whom the composition is administered ingests an alcoholic beverage either:

a. together with the composition, or

b. within a period of up to 60 minutes before and up to 60 minutes after ingesting the composition.

5. The immediate release pharmaceutical composition according to claim 1 , wherein the one or more effervescent agents comprise a water soluble organic acid and a water soluble bicarbonate.

6. The immediate release pharmaceutical composition according to claim 1 , wherein the polyglycol has a molecular weight selected from 1000, 1100, 1900, 2000, 2800, 2900, 3350, 4400, 5800, 6000, 8000, 8400, 10,000, 12,000, 14,600, and 17,000 Daltons.

7. The immediate release pharmaceutical composition according to claim 1 , wherein the one or more drug substances is selected from the group consisting of anaesthetics, analgesics, opioids, antipyretics, antimigraine agents, antiepileptics, anti-parkinson agents, dopaminergic agents, antipsychotics, anxiolytics, sedatives, antidepressants, psychostimulating agents used for ADHD and nootropics, and agents used in addictive disorders.

8. The immediate release pharmaceutical composition according to claim 7 , wherein the one or more effervescent agents comprise a water soluble organic acid and a water soluble bicarbonate.

9. The immediate release pharmaceutical composition according to claim 7 , wherein the polyglycol has a molecular weight selected from 1000, 1100, 1900, 2000, 2800, 2900, 3350, 4400, 5800, 6000, 8000, 8400, 10,000, 12,000, 14,600, or 17,000 Daltons.

10. The immediate release pharmaceutical composition according to claim 7 , wherein the composition is resistant to alcohol-induced dose dumping when the alcohol is ingested either:

a. together with the composition, or

b. within a period of up to 60 minutes before and up to 60 minutes after ingesting the composition.

11. The immediate release pharmaceutical composition according to claim 7 , wherein the one or more drug substances is released from the composition in the stomach with a release profile that is dependent on the concentration of ethanol, such that an increased ethanol concentration results in a decreased rate of drug release.

12. The immediate release pharmaceutical composition according to claim 1 , wherein the one or more disintegrants is selected from the group consisting of sodium starch glycolate, povidone, sodium alginate, alginic acid, calcium alginate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, powdered cellulose, chitosan, croscarmellose sodium, crospovidone, cross-linked polyvinylpyrrolidone, hydroxypropyl starch, hydroxypropyl cellulose low-substituted, magnesium aluminium silicate, methylcellulose, microcrystalline cellulose, pregelatinized starch, docusae sodium, guar gum, and polacrilin potassium.

13. The immediate release pharmaceutical composition according to claim 1 , wherein the concentration of the one or more disintegrants in the composition is in an amount selected from about 1% to about 60% by weight and about 5% to about 50% by weight.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2020
From: U.S. BANK NATIONAL ASSOCIATION
To: ZYLA LIFE SCIENCES, F/K/A EGALET CORPORATION; ZYLA LIFE SCIENCES US INC., F/K/A EGALET US, INC.; EGALET LIMITED
Reel/Frame 053411/0496 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded May 21, 2020
From: CANTOR FITZGERALD SECURITIES, AS AGENT AND AS COLLATERAL AGENT
To: ZYLA LIFE SCIENCES (F/K/A EGALET CORPORATION); ZYLA LIFE SCIENCES US INC. (F/K/A EGALET US, INC.); EGALET LIMITED
Reel/Frame 052740/0025 →
GRANT OF SECURITY INTEREST IN PATENTS Recorded Mar 20, 2019
From: EGALET CORPORATION; EGALET US, INC.; EGALET LIMITED
To: CANTOR FITZGERALD SECURITIES, AS COLLATERAL AGENT
Reel/Frame 050152/0828 →
CHANGE OF ADDRESS Recorded Oct 3, 2016
From: EGALET LTD.
To: EGALET LTD.
Reel/Frame 040293/0249 →
SECURITY INTEREST Recorded Aug 31, 2016
From: EGALET CORPORATION; EGALET US, INC.; EGALET LTD
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 039600/0791 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2010
From: EGALET A/S
To: EGALET LTD.
Reel/Frame 025095/0092 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2010
From: TYGESEN, PETER HOLM; OEVERGAARD, JAN MARTIN; OESTMAN, JOAKIM
To: EGALET A/S
Reel/Frame 024261/0878 →